BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29625272)

  • 1. Reporting bias in completed epilepsy intervention trials: A cross-sectional analysis.
    Rayi A; Thompson S; Gloss D; Malhotra K
    Epilepsy Res; 2018 Jul; 143():1-6. PubMed ID: 29625272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
    Zou CX; Becker JE; Phillips AT; Garritano JM; Krumholz HM; Miller JE; Ross JS
    Trials; 2018 Oct; 19(1):581. PubMed ID: 30352601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reporting Compliance of Stroke Trials: Cross-Sectional Analysis.
    Malhotra K; Rayi A; Khunger M; Thompson S; Liebeskind DS
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):1472-1480. PubMed ID: 28412315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study.
    DeVito NJ; Bacon S; Goldacre B
    Lancet; 2020 Feb; 395(10221):361-369. PubMed ID: 31958402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
    Miller JE; Korn D; Ross JS
    BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance with results reporting at ClinicalTrials.gov.
    Anderson ML; Chiswell K; Peterson ED; Tasneem A; Topping J; Califf RM
    N Engl J Med; 2015 Mar; 372(11):1031-9. PubMed ID: 25760355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compliance on Mandatory Data Reporting in Registered Obstetrics Trials.
    Checketts JX; Evans MB; Athale AH; Jawhar OM; Wright MR; Bryant K; Vassar M
    Am J Perinatol; 2018 Oct; 35(12):1192-1196. PubMed ID: 29695018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study.
    Prayle AP; Hurley MN; Smyth AR
    BMJ; 2012 Jan; 344():d7373. PubMed ID: 22214756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten Years after the International Committee of Medical Journal Editors' Clinical Trial Registration Initiative, One Quarter of Phase 3 Pediatric Epilepsy Clinical Trials Still Remain Unpublished: A Cross Sectional Analysis.
    Lampert A; Hoffmann GF; Ries M
    PLoS One; 2016; 11(1):e0144973. PubMed ID: 26735955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating publication bias for clinical trials supporting new dermatologic drug approvals from 2003 to 2018.
    Ravichandran S; Mulligan KM; Ezaldein HH; Scott JF
    Arch Dermatol Res; 2023 May; 315(4):831-838. PubMed ID: 36333459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with reporting results for pulmonary clinical trials in ClinicalTrials.gov.
    Riley IL; Boulware LE; Sun JL; Chiswell K; Que LG; Kraft M; Todd JL; Palmer SM; Anderson ML
    Clin Trials; 2018 Feb; 15(1):87-94. PubMed ID: 29121787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
    Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
    BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
    Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
    Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial reporting performance of thirty UK universities on ClinicalTrials.gov-evaluation of a new tracking tool for the US clinical trial registry.
    Keestra SM; Rodgers F; Lenz D; Osborne R; Bruckner T; Lee S
    Trials; 2021 Jun; 22(1):375. PubMed ID: 34074329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public availability of results of trials assessing cancer drugs in the United States.
    Nguyen TA; Dechartres A; Belgherbi S; Ravaud P
    J Clin Oncol; 2013 Aug; 31(24):2998-3003. PubMed ID: 23878298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA.
    Talebi R; Redberg RF; Ross JS
    Trials; 2020 Jul; 21(1):675. PubMed ID: 32703252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses.
    Roest AM; de Jonge P; Williams CD; de Vries YA; Schoevers RA; Turner EH
    JAMA Psychiatry; 2015 May; 72(5):500-10. PubMed ID: 25806940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States.
    Lassman SM; Shopshear OM; Jazic I; Ulrich J; Francer J
    BMJ Open; 2017 Sep; 7(9):e015110. PubMed ID: 28942418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fate of prospective spine studies registered on www.ClinicalTrials.gov.
    Ohnmeiss DD
    Spine J; 2015 Mar; 15(3):487-91. PubMed ID: 25315132
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.